| Today's Big NewsNov 8, 2022 |
|
Talent matters more than ever. And Greater Philadelphia’s growth and development of this critical asset is one reason JLL ranked the region as its No. 5 Life Sciences cluster in the U.S. Learn how the region can fuel your company’s growth. Learn more. 
|
|
| By Robert King As Republicans appear poised to take control of at least one chamber of Congress, experts say GOP lawmakers could scrutinize implementation of the Inflation Reduction Act. |
|
|
|
By Annalee Armstrong ADC Therapeutics seems to have run headlong into the FDA’s new strict policy on accelerated reviews: Get your confirmatory study in line before filing, or wait. |
By Zoey Becker Nearly two years after the rollout of COVID-19 vaccines, risks such as myocarditis are still being assessed. Researchers found that the risk of myocarditis is greater after a second dose of Moderna's shot compared with Pfizer/BioNTech's competing vaccine. |
By Andrea Park With FDA clearance secured for its Bluetooth-connected insulin dose-tracking technology, Eli Lilly is ready to pick up the tempo. |
|
Wednesday, November 16, 2022 | 11am ET / 8am PT Process characterization is an important step in the product development journey. Join this webinar where experts share case studies in developing a stepwise approach for process validation. Register now. 
|
|
By Fraiser Kansteiner Even though Bayer achieved gains across all three of its business sectors for the third quarter of 2022, the company has had to "contend with the current unfavorable business environment,” Bayer CEO Werner Baumann told investors on a conference call Tuesday. |
By James Waldron The efficacy of GSK's hepatitis B treatment may have dropped by over 60% between the interim and end-of-study analysis, but the Big Pharma is still hopeful the antisense oligonucleotide treatment will provide a functional cure for the infection. |
By Paige Minemyer UnitedHealth Group continues to lead the pack in profitability, according to the latest earnings reports for major national insurers. The ongoing expansion of the company's Optum subsidiary, which has been a significant growth engine over multiple quarters, is a blueprint that competitors are starting to follow. |
By James Waldron BioMarin’s hopes for bringing its hemophilia gene therapy to market remain just out of reach, with the FDA now requesting a look at its manufacturing site and long-term phase 3 data. |
By Andrea Park About a year after Acutus Medical’s shares first dipped below the $10 mark, the stock is now valued at a fraction of that price, putting it at risk of being booted from the Nasdaq. |
By Dave Muoio Charity care spending varies "substantially" across hospitals with just a third landing between 1% and 2% of their total operating expenses, per a recent analysis. Hospital mission, local need and loose government requirements all contribute to the wide spread. |
By Kevin Dunleavy Indian generics manufacturer Lupin has suspended production of drugs bound for the US from a troubled active pharmaceutical ingredient plant in India, according to an FDA warning letter. The regulator has asked Lupin to provide notification “before resuming operations.” |
By Gabrielle Masson Insilico Medicine is radiating heat amid the biotech winter, kindling its fires with a Sanofi collab that could be worth up to $1.2 billion in biobucks—the AI drug discovery company’s largest deal to date. |
By Conor Hale Embecta has signed an agreement with Intuity to co-promote the latter’s Pogo Automatic system among U.S. healthcare professionals. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
